Connect Biopharma Holdings Clinical Trial Data
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.
- Earnings call
- Sep 30, 2026, 8:00 AM ET